Biography:

Tirasak Pasharawipas completed his PhD from Faculty of Microbiology, Mahidol University, Bangkok, Thailand. He has his Postdoctoral training at Neuro Virology and Cancer biology Center, Temple University, Philadelphia. At present, he is a Full Professor in Microbiology and Immunology, Graduate Program of Medical Technology, Rangsit University, Thailand. He is interested in various academic subjects of science and liberal arts in addition to music and sports. His scientific fields mainly focus in viral and cellular interaction, bacteriophage and viral diseases in invertebrate animals. However, his research interests expand to viral vaccines, autoimmune disease and cancer biology including the relationship of MHC molecules to some specific diseases and viral vaccines. He enjoys being a reviewer for several journals and an advisor to develop young medical scientists with the wish that they would co-operate and succeed to solve all the problematic diseases, now and then, in a proper way with genuine scientific thinking.

Abstract:

The success to use subunit viral vaccine to prevent a particular viral infection is very limit. This is different from the time when the entire Cowpox virus was originally used for vaccination to prevent the smallpox viral epidemic over a thousand years ago in China before approved in a scientific way by Edward Jenner although immunity was not known. Knowledge of immunology has been profoundly discovered now-a-days. With a thought of safety reason to prevent side effects, subunit viral vaccine becomes the major choice for manufacturing viral vaccine. However, many kinds of viral vaccines could not reach our accomplishment. There is a question why viral vaccines cannot be effective for everybody. This is a question that we need to revise our knowledge and manipulate in the right direction for the viral vaccine production. To prevent a viral infection, a body must produce a protective antibody to prevent the particular viral particle to attach the viral receptor on a target cell. Theoretically, adaptive immunity needs induction not only by a particular antigen but also our cellular molecule called major histocompatibility complex (MHC) to form a complex molecule with its appropriate epitope to activate a specific receptor of T cell. There are two classes of MHC molecules called class I and class II. MHC class I is required for inducing cytotoxic T cell while MHC class II is for helper T cell. Helper T cell plays a key role to induce an effective stage of acquired immunity including a specific protective antibody. To produce the viral-specific antibody, MHC class II plays a key role to induce helper T cell and then B cell to synthesize a specific antibody. Since the MHC gene alleles are highly polymorphic so the possibility that individuals have the same gene alleles might be one in a million which, mostly, can be found in those who are an identical twin. Accordingly, a subunit viral vaccine, which contains a limit number of epitopes, would reduce a capacity of an antigen presenting cell, such as a dendritic cell, to process some epitopes to induce the particular helper T cell clones. Subsequently, in some people, the corresponding B cell clones cannot synthesize the specific antibody to neutralize the particular infectious viral particle. Moreover, the success of vaccination might require other different thoughts. We might need to understand more about the viral receptor on the target cells. There was a proposal of an inducible viral receptor concept which can be applied to protect viral infection as an additional strategy to produce the effective viral vaccines. Accordingly, this presentation will present the novel approach to develop the viral vaccine for everybody.

Biography:

Adwan S has completed his PhD from Queens University Belfast School of Pharmacy. He is working as Assistant Professor at Zarqa University School of Pharmacy. His research interest involves investigation of novel technologies and drug delivery systems for the treatment of otic and ophthalmic diseases.

Abstract:

Ocular drug delivery is currently one of the most challenging areas in modern drug delivery due to the unique anatomy and physiology of the eye and the presence of the ocular barriers. Accordingly, novel drug delivery methods have been investigated to enhance ocular drug permeation and increase the intraocular bioavailability. In this project, P.L.E.A.S.E. (Precise Laser Epidermal System; Pantec Biosolutions AG) laser technology was investigated, for the first time, to enhance ocular drug permeation. Two effects were revealed after laser treatment of ocular tissues. At high fluenes, micropores were created with scare formation around the pores due to the photo thermal effect of laser radiation. Lower fluences showed the formation of shallow pores and the disruption of the collagenous structure of ocular tissues. The effect of increasing the fluence and density of applied laser was investigated. Confocal microscopy studies revealed more intense dye distribution of rhodamine B, FITC-Dextran 70 kDa and FITC-Dextran 150 kDa after laser application. The transscleral and transcorneal permeation of rhodamine B was increased after laser application of 8.9 J/cm2 fluence and increasing the density of laser application. The transscleral water loss studies showed increased water loss after laser application which was decreased after 6 hours of application. As a conclusion, fractional ER: YAG laser is a promising and safe microporation technique that can be used to enhance the permeation of topically applied drugs. Tissue imaging, permeation, distribution studies and transscleral water loss studies showed that the laser application at low energies is promising for enhancing ocular drug permeation.

Biography:

Dimitrios A Lamprou is reader in Pharmaceutical Engineering and MSc Programme Director at the School of Pharmacy at Queen's University Belfast (UK) and Visiting Researcher at University of Strathclyde (Glasgow, UK). He has experience of teaching in higher education, conducting research and has 60+ publications, 200+ conference abstracts, 70+ oral/invited presentations) and securing national and international funding (£2M+). He is Secretary at the United Kingdom and Ireland Controlled Release Society (UKICRS), external PhD viva examiner for UK and International Institutions, and referees for journals, publishers and research funding bodies. His group is applying aspects of Pharmaceutical Technology to a range of areas such as cancer, antimicrobial resistance and nanomedicine development. The group research interests focused on four distinct areas like biosurface engineering, electrospinning, microfluidics and pharmaceutical 3D printing and bioprinting.

Abstract:

The talk will cover the challenges and opportunities in pharmaceutics by adopting new formulation technologies to bring new products into the market. 3D printing and electrospinning are an example of technologies that have been widely used in other industries, however are new to pharmaceutical manufacturing. Therefore, the use of these techniques in drug delivery and tissue engineering applications, including the use of state of the art techniques (e.g. FastScan AFM, ToF-SIMS, nanoCT) will be discussed. The first part will focus on the preparation of drug-loaded polymeric electrospun nanofibers. The purpose of this study is to examine any potential effects, chemical and mechanical, of drug loaded electrospun nano fiber scaffolds. Biodegradable polyesters that commonly used in biomedical applications for controlled release and targeted drug delivery was loaded and electrospun with different types of drugs. The electrospun fibres were characterised through various methods in order to measure the drug efficacy, antibacterial properties and drug-polymer interactions. There are a number of different applications within medicine that require materials to be developed with the optimal characteristics, such as their strength, rate of degradation and porosity as well as their shapes and sizes. 3D printing process was patented in 1986, however only recently have been utilised in the field of pharmaceutical printing. Therefore, in the second part, 3D printed systems (e.g. microneedles, rings and tablets) of various designs with high drug payloads that have been formulated using advanced additive technologies and characterised using advanced characterisation techniques will be discussed.

Biography:

Faongchat Jarintanan has completed her PhD from Srinakharinwirot University at Thailand in 2010. During the academic year 1998-2018, she is the Lecturer in Molecular Genetic and Hematology at Faculty of Medical Technology, Rangsit University. She got grant for research at Hiroshima University to study development of production system for foreign protein by exploiting transgenic green algae in 2003. She has research focuses on  natural product, cell culture, bioprinting with cells and SNPs gene of Alzheimer's disease.

Abstract:

Colon cancer  is the most common cancer worldwide. Recently, natural products have been used for the treatment of cancer and becoming an important research area for drug discovery. Terrein, a fungal metabolite derived from Aspergillus terreus, has been shown to have a variety of biological activities to exhibit selective anticancer activity in human including colon cancer. However, cytotoxic effects of terrrein against human colon cancer cell lines have never been studied. Therefore, the present study was observed the cytotoxic effects of terrein by using the MTT assay. The sensitivity was evaluated by comparing the effect to COLO205 cells with vero cells for 24h. The results of MTT assay showed that terrein was cytotoxic to COLO205 with IC₅₀ at 0.05 mM, but not to normal Vero epithelial cell line. The induction of cell death was further investigated by observing the cellular morphology of nuclei using Hoechst 33342 staining, a DNA specific dye.  The result showed that the treated cancer cells had increased of nuclear condensation and fragmentation with 0.05, 0.15, 0.2, 0.25, 0.3 mM at 6 h by observing under the phase contrast inverted microscopy. These data supported that the mode of cell death induction of terrein possibly activated via apotosis mechanism. Thus, terrein is an interesting compound that might be a development for colon cancer treatment. However, investigation through the mechanism of action is needed.

Biography:

Julia Matsuieva is a PhD researcher at the University of Wroclaw, Poland. Her scientific interests are on pricing strategies on the pharmaceutical market, local legal requirement for drug pricing, access to the medicines, quality life of people, generic medicines. She is the author of scientific publications in Poland, Ukraine and Slovakia. Her Doctoral thesis is dedicated to the consumer’s behavior in the Polish pharmaceutical market.

Abstract:

Biography:

Tirasak Pasharawipas completed his PhD from Faculty of Microbiology, Mahidol University, Bangkok, Thailand. He has his Postdoctoral training at Neuro Virology and Cancer biology Center, Temple University, Philadelphia. At present, he is a Full Professor in Microbiology and Immunology, Graduate Program of Medical Technology, Rangsit University, Thailand. He is interested in various academic subjects of science and liberal arts in addition to music and sports. His scientific fields mainly focus in viral and cellular interaction, bacteriophage and viral diseases in invertebrate animals. However, his research interests expand to viral vaccines, autoimmune disease and cancer biology including the relationship of MHC molecules to some specific diseases and viral vaccines. He enjoys being a reviewer for several journals and an advisor to develop young medical scientists with the wish that they would co-operate and succeed to solve all the problematic diseases, now and then, in a proper way with genuine scientific thinking.

Abstract:

Vitamin B12 or cobalamin is essential for the major parts of the human body which are nerves, blood, and skeletal system. The major source of vitamin B12 is animal products. Vitamin B12 deficiency is common in vegan and vegetarians but the reports also become increased in elderly while human-life span keeps proliferating. There are more than 20 forms of vitamin B12 analogues but only two forms account as the natural active forms in the human body. Besides insufficient consumption of the vitamin B12, ingestion, transportation and the activity of the cobalamin in a body are also the causes of the deficiency. This presentation will give an overview concerning vitamin B12 and the known causes of its deficiency. However, the mechanism and homeostasis of vitamin B12 are truly complicated. Accordingly, the opinions for future approaches to study for developing the key information of the vitamin B12 for the general application in public health care will be proposed.